IMV Strategic Partnership Investor Presentation
Filed with ASX · · 6 pages · English
Vitrafy has entered into a strategic, commercial agreement to work with global leader, IMV, on animal reproduction cryopreservation Strategic Commercial Agreement With global, animal reproduction leader, IMV Technologies (“IMV”). Revenue Generative Vitrafy will receive up to A$480k in monthly fees over the 12-month term, plus milestone payments of up to A$450k. Product Alignment Partnership to int
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Earlier from Vitrafy Life Sciences
- Q1 FY26 Quarterly Activities Report and Appendix 4C
- FY25 Full Year Results Presentation - Amended
- FY25 Appendix 4E and Annual Report
- FY25 Full Year Results Presentation
- Leadership Transition at Vitrafy
Later from Vitrafy Life Sciences
- Q2 FY26 Quarterly Activities Report and Appendix 4C
- FY26 Appendix 4D and Half Year Report
- FY26 Half Year Results Presentation
- USAISR Completes Phase 2 Platelet Study
- Q3 FY26 Quarterly Activities Report and Appendix 4C
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences